A Phase 1 interventional study of KarXT and KarX-EC in Psychiatric Disorders, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-06.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.
1,745 studies on the registry are indexed under Mental Disorders; 352 are open to participants now.
This study's enrollment of 24 is below the median of 100 across 1,304 interventional studies indexed under Mental Disorders.
Browse Mental Disorders studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed , Fifth Edition, Text Revision (DSM-5-TR) psychiatric diagnosis of 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KarXT
Drug: KarXT · Drug: KarX-EC
Drug: KarXT · Drug: KarX-EC
Drug pages: Xanomeline · Trospium
Specified dose on specified days
Also known as: Xanomeline and Trospium Chloride Capsule, BMS-986510
Specified dose on specified days
Also known as: Xanomeline Enteric-coated, BMS-986519
Number of participants with Adverse Events (AEs)
Time frame: Up to Day 43
Number of participants with Serioues AEs (SAEs)
Time frame: Up to Day 43
Number of participants with AEs of Special Interest (AESIs)
Time frame: Up to Day 43
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 15
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Time frame: Up to Day 15
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to Day 15
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to Day 15
Concentration at the end of a dosing interval (Ctau)
Time frame: Up to Day 15
Cmax accumulation index (AI_Cmax)
Ratio of maximum observed plasma concentration at steady-state on Day 5 to maximum observed plasma concentration after first dose
Time frame: Up to Day 15
AUC accumulation index (AI_AUC)
Ratio of area under the concentration-time curve in 1 dosing interval at steady-state on Day 5 to area under the concentration-time curve in 1 dosing interval after first dose
Time frame: Up to Day 15
Ctau accumulation index (AI_Ctau)
Ratio of concentration at the end of the dosing interval at steady-state on Day 5 to maximum observed plasma concentration after first dose
Time frame: Up to Day 15
Average concentration within a dosing interval at steady-state (Css-avg)
Time frame: Up to Day 15
Apparent total body clearance (CLT/F)
Time frame: Up to Day 15
Effective elimination half-life during dosing interval (T-HALF(eff))
Time frame: Up to Day 15
T-HALFeff based on AUC observed (T-HALFeff_AUC)
Effective elimination half-life based on degree of area under the plasma concentration-time curve accumulation observed
Time frame: Up to Day 15
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Apr 2025 to primary completion in Jul 2025, 2 months.
Of 27 phase 1 interventional studies under Mental Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 43. This study's 2 months is below that.
Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium